David Loeb

Professor

Albert Einstein College of Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (27)

Ewing sarcoma is an aggressive bone and soft-tissue cancer affecting adolescents and young adults. In vitro and in vivo models of Ewing sarcoma have been instrumental in advancing our understanding of Ewing sarcoma biology and essential in evaluating potential therapies, particularly for metastatic or relapsed disease for which effective treatment options remain limited. Through an international collaborative effort between the Children’s Oncology Group Bone Tumor Committee and the Euro Ewing Consortium, we review the current landscape of preclinical modeling used in Ewing sarcoma research encompassing both in vitro (cell lines and tumor organoids) and in vivo (mouse and nonmammalian xenografts) model systems. We discuss factors that can influence experimental results, provide testing considerations for both in vitro and in vivo studies, and descriptions of existing preclinical data repositories. We highlight current needs in Ewing sarcoma modeling and the importance of enhanced international cooperative research and patient advocacy efforts which will be critical in expanding our resources of biologically relevant Ewing sarcoma models to enable translation of preclinical findings into effective therapeutic strategies for patients with Ewing sarcoma.

Year:

2026

Supplementary Figure S4: DFMO inhibits sarcosphere formation. Quantification of the data presented in Figure 2. The indicated cells were grown in non-adherent conditions with non-differentiating media and treated with the indicated concentration of DFMO, in 5 mM DFMO supplemented with spermidine (5 µM) and aminoguanidine (1 mM), with spermidine and aminoguanidine alone, or with 10 mM DFMO for 5 days beginning after 5 days to allow spheroids to form. Indicated conditions were statistically significantly different from each other by Student’s t test.

Year:

2025

Supplementary Figure S3: DFMO causes a cell cycle arrest. Histograms demonstrate the percentage of TC71 cells (A) and SK-ES-1 cells (C) in the G1 (purple), S (yellow), and G2/M (green) phases of the cell cycle in control cultures and in cultures treated with DFMO at the IC50 estimated from the proliferation assays (TC71: 650 µM, SK-ES1: 1 mM, MHH-ES1: 2 mM) for 72 hours. Representative results of experiments performed 2 separate times are shown. Quantification of the histograms in panel A are shown in panel B, and quantification of the histograms in panel C are shown in panel D. Statistical significance of the difference in overall distribution of cells within the cell cycle was tested using the χ 2 test.

Year:

2025

Supplementary Figure S9: DFMO-mediated inhibition of sarcosphere formation is rescued by inhibitors of ferroptosis but not by inhibition of apoptosis. MHH-ES1 cells (A) and SK-ES1 cells (B) were grown in non-adherent conditions with non-differentiating media and treated with either DFMO (1 or 5 mM, as indicated) or 1 mM DFMO supplemented with Spermine/Aminoguanidine, Ferrostatin-1, Liproxstatin-1, N-acetylcysteine (NAC), or Q-VD-OPh. + indicates 1 mM DFMO. P indicates cells treated with 10 mM DFMO after spheroid formation. Spheroid formation was quantified in triplicate samples, and experiment was repeated 3 times. 1 mM DFMO caused a statistically significant decrease in spheroid formation (MHH-ES1 p = 0.0039, SK-ES1 p = 0.0023). Ferrostatin (MHH-ES1 p = 0.0006, SK-ES1 p = 0.0023), liproxstatin (MHH-ES1 p = 0.0065, SK-ES1 p = 0.0005)), and NAC (MHH-ES1 p = 0.007, SK-ES1 p = 0.0002) each caused a statistically significant increase in spheroid formation in the presence of 1 mM DFMO compared with 1 mM DFMO alone. In contrast, Q-VD did not rescue spheroid formation in the presence of 1 mM DFMO. None of the cell death inhibitors (spermidine, ferrostatin, liproxstatin, NAC, or Q-VD-OPh) resulted in a statistically different number of spheroids compared to untreated cells.

Year:

2025

Supplementary Figure S10: Dissemination of Ewing sarcoma tumor cells alters the expression of multiple ferroptosis-related genes. Normalized read counts of key genes from the RNA-seq experiment described in Figure 5. In brief, tumors composed of TdTomato-labeled TC-71 cells were implanted in the tibias of NSG mice. When tumors reached 1.5 cm in diameter, Ewing sarcoma cells were recovered from lungs, bone marrow, and the primary tumor by flow cytometry. RNA was isolated from these cells and analyzed by RNA sequencing.

Year:

2025

Supplementary Figure S1: DFMO inhibits Ewing sarcoma proliferation in vitro. TC71 cells (A) and SK-ES-1 cells (D) were treated with DFMO at various concentrations. Error bars represent 95% confidence interval for triplicate evaluation of each sample. This data is representative of 3 independent experiments demonstrating a dose-dependent inhibition of proliferation with exposure to DFMO. TC71 cells (B) and SK-ES-1 cells (E) were treated with the indicated concentrations of DFMO. After 4 days, DFMO was removed and replaced with fresh media without DFMO. Resumption of proliferation was observed in all 3-cell lines. TC71 cells (C) and SK-ES-1 cells (F) were treated with the indicated concentrations of DFMO. After 4 days, fresh DFMO was added with or without the addition of spermidine (5 µM) and aminoguanidine (1 mM). Proliferation was measured over an additional 6 days utilizing the Incucyte Live-Cell Analysis System, and cells were noted to proliferate in cultures supplemented with spermidine and aminoguanidine.

Year:

2025

Purpose: Despite decades of clinical trials, no progress has been made in improving the survival of patients with Ewing sarcoma who either present with metastatic disease or suffer a metastatic relapse. In our preclinical models, we found differential levels of polyamines in tumors that metastasize compared with tumors that do not, leading us to investigate the potential for D,L-α-difluoromethylornithine (DFMO), an inhibitor of polyamine synthesis, to prevent Ewing sarcoma metastasis. Experimental Design: The effect of DFMO on Ewing sarcoma cell lines in vitro was studied by measuring proliferation, sphere formation, and clonogenic growth in soft agar. The effect in vivo was investigated using our orthotopic implantation/amputation model of metastasis. Transcriptomic changes were evaluated by RNA sequencing. Results: DFMO causes a cell cycle arrest and inhibits both sarcosphere formation and clonogenic growth in soft agar. In vivo , DFMO slows primary tumor growth and inhibits metastasis. RNA sequencing demonstrated gene expression patterns consistent with induction of ferroptosis caused by polyamine depletion, which was validated in vitro by demonstrating that DFMO treatment induces lipid peroxidation, and ferrostatin-1 and liproxstatin-1 allow sphere formation even in the presence of DFMO. Conclusions: DFMO slows the growth of Ewing sarcoma cells in vitro , with a profound impact on sphere formation and clonogenic growth, and affects all aspects of Ewing sarcoma tumorigenesis, including tumor initiation, tumor growth, and metastasis, probably through induction of ferroptosis mediated by polyamine depletion. Our results provide preclinical justification to test the ability of DFMO to prevent metastatic recurrence in patients with Ewing sarcoma.

Year:

2025

Supplementary Figure S8: DFMO induces lipid peroxidation. Twenty thousand MHH-ES1 cells (A and B) or SK-ES1 cells (C and D) were plated in ultra-low attachment plates and treated with (B and D) or without (A and C) 5 mM DFMO. After 24 hours, cells were collected, incubated with 5 µM BODIPY581/591 for 30 minutes, and green and red fluorescence was evaluated by flow cytometry. The amount of green fluorescence reflects the amount of peroxidated lipid. In control conditions, only 3.54% of the MHH-ES1 cells and 22.8% of the SK-ES1 cells exhibited green fluorescence, whereas 25.1% of DFMO-treated MHH-ES1 cells and 41.4% of DFMO-treated SK-ES1 cells exhibited green fluorescence.

Year:

2025

Supplementary Figure S6: 2% DFMO diminishes polyamine production in vivo. Fragments of the JHHESX3 PDX were implanted in NSG mice either subcutaneously or in the tibia (orthotopic) and mice were randomly assigned to receive either regular drinking water or water supplemented with 2% DFMO (w/v). (A) Concentrations of both putrescine (p = 0.0001) and spermidine (p = 0.024) measured in the urine from mice with orthotopic tumors were significantly lower in DFMO-treated mice compared to control. (B) Ornitine Decarboxylase (ODC) activity was lower in orthotopic tumors compared with subcutaneous tumors (p = 0.014), and ODC activity was also lower in DFMO-treated mice with orthotopic tumors compared with control (p = 0.018). Polyamine levels were measured in tumor samples excised from tumors implanted subcutaneously (C) or orthotopically (D). Regardless of site of implantation, levels of both putrescine and spermidine were lower in tumors collected from DFMO-treated mice compared with control. DFMO treatment did not affect the concentration of spermine, as has been previously reported (40).

Year:

2025

Supplementary Figure S7: DFMO does not induce caspase activity. 300,000 MHH-ES1 cells (A) or SK-ES1 cells (B) were plated in RPMI + 10% FBS. After 24 hours, the media was removed, and fresh media supplemented with Incucyte Caspase-3/7 Dye for Apoptosis was added. DFMO was added at the indicated concentrations of 0.5 µM to 10 mM. Etoposide (3 µM) was used as a positive control. Plates were inserted into the Incucyte Live-Cell Analysis System and caspase activity was measured utilizing live-cell time-lapse imaging at 24 hours. Error bars represent 95% confidence interval for triplicate evaluation of each sample. This data is representative of 3 independent experiments. Whereas etoposide treatment results in profound activation of caspase 3 in all 3 cell lines tested, this was not detected in cells treated with DFMO, even at the highest doses tested. ** = p

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Collaborators (26)

Eric Sandler

Department Chair

Nemours Children's Health System

UNITED STATES
View details

Christine A Pratilas

Vice Chair for Pediatric Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

Zhanjun Hou

Professor (Research)

Wayne State University

UNITED STATES
View details

Patrick Grohar

Professor of Pediatrics

University of Michigan

UNITED STATES
View details

Alice Soragni

University of California

UNITED STATES
View details

Tracy Murray Stewart

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Javier Oesterheld

Clinical (Full) Professor

Wake Forest University

UNITED STATES
View details

Shrey Patel

Albert Einstein College of Medicine

UNITED STATES
View details

Eleni Marina Tomazou

-

AUSTRIA
View details

Kelly M. Bailey

Associate Professor, Director AYA Translational Oncology

Mayo Clinic

UNITED STATES
View details

Robert Casero

Professor and Associate Director

Johns Hopkins University School of Medicine

UNITED STATES
View details

Masanori Hayashi

Assistant Professor

University of Colorado Boulder

UNITED STATES
View details

Adam Shlien

Wellcome Sanger Institute

UNITED KINGDOM
View details

Yuqi Tan

Stanford University

UNITED STATES
View details

Leo Mascarenhas

Division Chief and Director, Pediatric Hematology-Oncology, Guerin Children's; Director, Sarcoma Program, Cedars-Sinai Cancer

Cedars-Sinai Medical Center

UNITED STATES
View details

Joyce Ohm

Chair, John and Santa Palisano Endowed Chair

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

James Amatruda

Chief

University of Southern California Keck School of Medicine

UNITED STATES
View details

Shireen Ganapathi

Assistant Professor of Pediatrics

University of Washington

UNITED STATES
View details

Jun Yin

Associate Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Brooke Fridley

Director

Children's Mercy Hospital

UNITED STATES
View details

Patrick Cahan

johns hopkins university school of medicine 1 department of biomedical engineering

UNITED STATES
View details

Hongwen Deng

Founding Director

Tulane University School of Medicine

UNITED STATES
View details

Emi Caywood

Director, Transplant and Cellular Therapy

Alfred I DuPont Hospital for Children

UNITED STATES
View details

Matteo Trucco

Associate Professor

Cleveland Clinic

UNITED STATES
View details

Scott Borinstein

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Lars Wagner

division of pediatric hematology‐oncology duke university medical center durham north carolina usa

UNITED STATES
View details